**12-December-2019** Version: 1.1



# **Riluzole Tablets**

# SAFETY DATA SHEET

North America GHS

According to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations & the Hazardous Products Regulation (February 11, 2015) & NORMA Oficial Mexicana NOM-018-STPS-2015

### 1. IDENTIFICATION

Product identifier

**Product Name:** Riluzole Tablets **Synonyms:** Riluzole Tablets, USP 50 mg **Other means of identification** 

Other Information: No other information

Recommended use of the chemical and restrictions on use Recommended Use: Pharmaceutical. Use only as directed.

The intent of this safety data sheet (SDS) is to provide safety information for occupational handling of this product. This information may not be relevant for medical use of this product. Patients/ consumers should consult the package insert/ product label/ physician/ pharmacist for information regarding the usage of this product. For information on the ingredients used in this product, refer to the appropriate SDS for each ingredient.

Uses advised against: No information available.

Details of the supplier of the safety data sheet

Mylan Inc.

Robert J. Coury Global Center

1000 Mylan Blvd.

Canonsburg, PA 15317, USA

+1.724.514.1800

Contact e-mail: SDScontact@mylan.com

**Emergency telephone number** 

**Emergency Telephone:** 24 hr. Emergency Contact ChemTel

**International:** +1-813-248-0585 **US & Canada:** 1-800-255-3924

Mexico: 800-099-0731

**Other Contact Information** 

**FDA Adverse Events Reporting** For reporting adverse health events call:

**Number:** +1 877-446-3679

### 2. HAZARDS IDENTIFICATION

Pharmaceutical Agent – Handling of this product in its final form presents minimal occupational exposure risk

**Patients/Consumers:** Please refer to the product information insert or product label for appropriate consumer-specific information about this product when used according to the physician's directions

This product is a drug, as defined by the US Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) and by Canada's Food and Drugs Act. It is in solid, final form for direct administration to the patient. Therefore, is it exempt from the US 2012 Hazard Communication Standard, as defined in the 29 CFR 1910.1200(b)(6)(vii) and in Canada's Hazardous Products Act

Classification

Not classified

**Label elements** 

Not classified

Other Hazards

No information available.

**Unknown acute toxicity** 

No information available

1/6

Riluzole Tablets NA SDS

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

This product is a drug, as defined by the US Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) and by Canada's Food and Drugs Act. It is in solid, final form for direct administration to the patient. Therefore, is it exempt from the US 2012 Hazard Communication Standard, as defined in the 29 CFR 1910.1200(b)(6)(vii) and in Canada's Hazardous Products Act

### 4. FIRST AID MEASURES

This is a pharmaceutical product in its final form. The risk of harmful exposure in the workplace is limited; however, the following guidance may be used as needed.

### **Description of first aid measures**

Overdose: Refer to information on package labeling and packaging. In case of overdose, get medical help or contact a Poison Control Center right away.

**General advice:** Show this safety data sheet to the doctor in attendance.

**Inhalation:** IF INHALED: Remove to fresh air and keep at rest in a position comfortable for breathing. Get medical attention immediately if symptoms occur.

Skin contact: Wash off immediately with soap and plenty of water. If skin irritation or rash occurs: Get medical advice/attention.

Eye contact: In case of eye contact, immediately flush eyes with plenty of water for at least 15 minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice/attention.

Ingestion: Do NOT induce vomiting. Clean mouth with water and drink afterwards plenty of water. Never give anything by mouth to an unconscious person. Get medical attention.

Self-protection of the first aider: First aider: Pay attention to self-protection. Do not breathe dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. Use personal protective equipment as required.

# Most important symptoms and effects, both acute and delayed

Symptoms: Fatigue, Nausea, Dizziness, and Abdominal pain. May cause respiratory impairment and lung damage.

Chronic symptoms: May cause damage to the following organs through prolonged or repeated exposure: Liver.

# Indication of any immediate medical attention and special treatment needed

Treat symptomatically. In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).

### 5. FIRE-FIGHTING MEASURES

# Extinguishing media

Suitable Extinguishing Media: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

**Unsuitable extinguishing media:** None known. Specific hazards arising from the chemical

Fire hazard: Not flammable.

**Explosive hazard:** Not an explosive.

Reactivity: Hazardous reactions will not occur under normal conditions.

Hazardous combustion products: Carbon oxides. Nitrogen oxides. Oxides of sulfur. Fluorinated oxides.

Advice for firefighters

Precautionary measures in case of fire: Standard procedure for chemical fires. Firefighting instructions: Use water spray or fog; do not use straight streams.

Protection of Firefighters: Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear.

**Other Information:** Refer to Section 9 for flammability properties.

# 6. ACCIDENTAL RELEASE MEASURES

This is a pharmaceutical product in its final form. The risk of harmful exposure in the workplace is limited; however, the following guidance may be used as needed.

### Personal precautions, protective equipment and emergency procedures

Personal precautions: Ensure adequate ventilation. Use personal protective equipment as required. Evacuate personnel to safe areas.

### For non-emergency personnel

Personal Protective Equipment: Use personal protective equipment as required.

**Emergency procedures:** Evacuate personnel to safe areas.

For emergency responders

**Personal Protective Equipment:** Use personal protective equipment as required.

**Emergency procedures:** Evacuate personnel to safe areas. Ventilate the area. Eliminate all ignition sources if safe to do so.

**Other Information:** Refer to protective measures listed in Sections 7 and 8.

# **Environmental precautions**

12-December-2019

Do not flush into surface water or sanitary sewer system. Should not be released into the environment. See Section 12 for additional Ecological Information.

### Methods and material for containment and cleaning up

**Methods for containment:** Prevent further leakage or spillage if safe to do so.

Methods for cleaning up: Use appropriate personal protective equipment (PPE). Carefully shovel or sweep up spilled material and place in

2/6

Riluzole Tablets NA SDS

suitable container. Avoid generating dust. For spills:. Soak up with inert absorbent material. Use clean non-sparking tools to collect absorbed material. Avoid breathing dust or spray mist.

**Prevention of secondary hazards:** Clean contaminated objects and areas thoroughly observing environmental regulations.

### Reference to other sections

See section 8 for more information. See section 13 for more information.

### 7. HANDLING AND STORAGE

### **Precautions for safe handling**

**Patients/Consumers:** Patients should adhere to the instructions provided within the product information insert or product label for appropriate consumer-specific information about this product when used according to the physician's directions.

Advice on safe handling: Handle in accordance with good industrial hygiene and safety practice. Ensure adequate ventilation.

### Conditions for safe storage, including any incompatibilities

**Storage Conditions:** Keep at temperatures between 20 and 25 °C (68 and 77 °F). Protect from light. Keep containers tightly closed in a dry, cool and well-ventilated place. Keep out of the reach of children.

Specific end use(s): Pharmaceutical. Use only as directed. Refer to product insert for usage instructions and product information.

# 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

This is a pharmaceutical product in its final form. The risk of harmful exposure in the workplace is limited; however, the following guidance may be used as needed.

### **Control parameters**

Exposure Limits: No information available

### **Exposure controls**

**Appropriate engineering controls:** Site-specific risk assessments should be conducted to determine the appropriate exposure control measures. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits.

### Individual protection measures, such as personal protective equipment

Hand protection: Wear protective gloves made from PVC, neoprene, nitrile, vinyl, or PVC/NBR.

**Eve/face protection:** Safety glasses with side shields are recommended for medical or industrial exposures.

**Skin and body protection:** Wear suitable protective clothing. **Respiratory protection:** Use appropriate respiratory protection.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

### Information on basic physical and chemical properties

Physical state:SolidAppearance:TabletsColor:White

Odor: No data available **Odor threshold:** No data available No data available pH: **Melting point / freezing point:** No data available **Boiling point / boiling range:** No data available Flash point: No data available No data available **Evaporation rate:** Flammability (solid, gas): No data available **Upper flammability limit:** No data available No data available Lower flammability limit: No data available Vapor pressure: Vapor density: No data available No data available Relative density: No data available Water solubility: Solubility in other solvents: No data available Partition coefficient: No data available **Autoignition temperature:** No data available No data available **Decomposition temperature:** No data available Kinematic viscosity: **Dynamic viscosity:** No data available **Explosive properties:** No data available **Oxidizing properties:** No data available

**Other Information** 

**VOC Content (%):** No data available

Riluzole Tablets NA SDS

# 10. STABILITY AND REACTIVITY

### Reactivity

Hazardous reactions will not occur under normal conditions.

# **Chemical stability**

Stable under normal conditions.

### Possibility of hazardous reactions

None under normal processing.

### Conditions to avoid

Extremes of temperature and direct sunlight.

### **Incompatible materials**

Strong oxidizing agents, strong acids, and strong bases.

# Hazardous decomposition products

Decomposition will not occur under normal conditions.

### 11. TOXICOLOGICAL INFORMATION

# **Information on toxicological effects**

# Information on likely routes of exposure

**Inhalation:** Not an expected route of exposure.

Ingestion: Ingestion may cause gastrointestinal irritation, nausea, vomiting and diarrhea. May cause adverse liver effects.

**Eye contact:** Not an expected route of exposure. **Skin contact:** Not an expected route of exposure.

Symptoms related to the physical, chemical and toxicological characteristics

**Symptoms:** Fatigue, Nausea, Dizziness, and Abdominal pain. May cause respiratory impairment and lung damage.

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Skin corrosion/irritation: Based on available data, the classification criteria are not met.

Serious eye damage/eye irritation: Based on available data, the classification criteria are not met.

Respiratory or skin sensitization: Not applicable.

Germ cell mutagenicity: Based on available data, the classification criteria are not met. Carcinogenicity: Based on available data, the classification criteria are not met. **Reproductive toxicity:** Based on available data, the classification criteria are not met. STOT - single exposure: Based on available data, the classification criteria are not met.

**STOT - repeated exposure:** May cause damage to organs (liver).

**Aspiration hazard:** Based on available data, the classification criteria are not met.

Numerical measures of toxicity Acute toxicity: No information available

### 12. ECOLOGICAL INFORMATION

### **Ecotoxicity**

Harmful to aquatic life.

#### Persistence and degradability

No information available.

#### Bioaccumulation

No information available.

### **Mobility**

No information available.

### Other adverse effects

No information available.

### 13. DISPOSAL CONSIDERATIONS

### Waste treatment methods

Dispose of contents/container in accordance with local, regional, national, and international regulations as applicable. Dispose of waste in accordance with environmental legislation. Do not flush into surface water or sanitary sewer system.

### 14. TRANSPORT INFORMATION

Transportation requirements can vary based on numerous factors such as regional regulations and shipment volume. It is the responsibility of the transporting organization to ensure compliance with all applicable laws and regulations regarding the transportation of this product.

# In accordance with DOT / ICAO / IATA / TDG

### **UN Number**

12-December-2019

UN 3249

# UN proper shipping name

4/6

Riluzole Tablets NA SDS

Medicine, solid, toxic, n.o.s. (Riluzole)

## Transport hazard class(es)

Hazard Class: 6.1



### Packing group

III

### **Environmental hazards**

No

# Special precautions for user

No information available

### Transport in bulk according to Annex II of MARPOL and the IBC Code

Not applicable

# **Special Provisions**

Shipper, please take note that in addition to limited and/or excepted quantity exemptions, the following Special Provisions may apply to this product. **US DOT:** [DOT - ORM-D]: CFR Title 49 §173.153 - (c) *Consumer commodities*. Until December 31, 2020, a limited quantity package of poisonous material in Packing Group III or a drug or medicine in Packing Group II or III that is also a "consumer commodity" as defined in §171.8 of this subchapter, may be renamed "Consumer commodity" and reclassed as ORM-D

**TDG:** TDG - 16: TDG - 38

**IMDG:** [IMDG - 221]: Substances included under this entry shall not be of packing group I; [IMDG - 223]: If the chemical or physical properties of a substance covered by this description are such that, when tested, it does not meet the established defining criteria for the class or division listed in column 3, or any other class or division, it is not subject to the provisions of this Code except in the case of a marine pollutant where 2.10.3 applies

IATA: IATA - A3

### 15. REGULATORY INFORMATION

### Safety, health and environmental regulations/legislation specific for the substance or mixture

**International Regulations** 

Ozone-depleting substances (ODS): Not applicable Persistent Organic Pollutants: Not applicable The Rotterdam Convention: Not applicable

**US Federal Regulations** 

**SARA 313:** Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372.

# CWA (Clean Water Act)

This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40 CFR 122.42).

## **CERCLA**

This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and Reauthorization Act (SARA) (40 CFR 355). There may be specific reporting requirements at the local, regional, or state level pertaining to releases of this material.

# **U.S. State Right-to-Know Regulations**

# **US State Regulations:**

Chemical name	New Jersey	Massachusetts	Pennsylvania
Cellulose Microcrystalline	X	X	X
9004-34-6			
Colloidal Silicon Dioxide	-	X	X
7631-86-9			

#### <u>Canada</u>

This product has been classified in accordance with the hazard criteria of the Controlled Products Regulations (CPR) and the SDS contains all the information required by the CPR.

# 16. OTHER INFORMATION

**Revision Date:** 12-December-2019

Other Information: This document has been prepared in accordance with standards for workplace safety. The

precautionary statements and warning included might not apply in all cases. Your needs may vary

\_\_\_\_\_

Riluzole Tablets NA SDS

depending on the potential for exposure in your workplace.

# Key or legend to abbreviations and acronyms used in the safety data sheet:

Legend, Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

TWA: TWA (time-weighted average)
STEL: STEL (Short Term Exposure Limit)

### Party responsible for the preparation of this document:

Mylan Global Environmental, Health, and Safety Department - Occupational Toxicology

Phone number: +1 304-559-2595

This SDS has been prepared for occupational exposure and intended to address some end-user concerns; however, patients/consumers are also strongly encouraged to review the product information insert or product label for consumer-specific information about this product. Patients/Consumers: Refer to the package insert or product label for appropriate consumer-specific information about this product when used according to manufacturer's directions. To the best of our knowledge, the information contained herein is accurate. However, neither the above named supplier nor any of its subsidiaries assumes any liability whatsoever for completeness of the information herein. Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.

Mylan GEHS NA GHS SDS 2017